- Home
- ERAS vs PSNL Comparison
ERAS vs PSNL Comparison
Compare ERAS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- PSNL
- Stock Information
- Founded
- ERAS 2018
- PSNL 2011
- Country
- ERAS United States
- PSNL United States
- Employees
- ERAS N/A
- PSNL N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- ERAS Health Care
- PSNL Health Care
- Exchange
- ERAS Nasdaq
- PSNL Nasdaq
- Market Cap
- ERAS 484.4M
- PSNL 484.0M
- IPO Year
- ERAS 2021
- PSNL 2019
- Fundamental
- Price
- ERAS $1.58
- PSNL $4.78
- Analyst Decision
- ERAS Strong Buy
- PSNL Strong Buy
- Analyst Count
- ERAS 6
- PSNL 4
- Target Price
- ERAS $4.50
- PSNL $8.13
- AVG Volume (30 Days)
- ERAS 714.7K
- PSNL 1.1M
- Earning Date
- ERAS 08-12-2025
- PSNL 08-05-2025
- Dividend Yield
- ERAS N/A
- PSNL N/A
- EPS Growth
- ERAS N/A
- PSNL N/A
- EPS
- ERAS N/A
- PSNL N/A
- Revenue
- ERAS N/A
- PSNL $80,317,000.00
- Revenue This Year
- ERAS N/A
- PSNL N/A
- Revenue Next Year
- ERAS N/A
- PSNL $29.83
- P/E Ratio
- ERAS N/A
- PSNL N/A
- Revenue Growth
- ERAS N/A
- PSNL 0.36
- 52 Week Low
- ERAS $1.01
- PSNL $2.83
- 52 Week High
- ERAS $3.31
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- ERAS 53.64
- PSNL 43.13
- Support Level
- ERAS $1.44
- PSNL $4.44
- Resistance Level
- ERAS $1.64
- PSNL $5.03
- Average True Range (ATR)
- ERAS 0.10
- PSNL 0.26
- MACD
- ERAS 0.01
- PSNL 0.06
- Stochastic Oscillator
- ERAS 61.54
- PSNL 63.24
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.